DYSGERMINOMA

Clinical trials for DYSGERMINOMA explained in plain language.

Never miss a new study

Get alerted when new DYSGERMINOMA trials appear

Sign up with your email to follow new studies for DYSGERMINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New immune therapy tested for Tough-to-Treat testicular and ovarian cancers

Disease control Ongoing

This study is testing whether two immunotherapy drugs, durvalumab and tremelimumab, can help control germ cell tumors that have returned or stopped responding to standard treatments. The trial is enrolling 30 adults whose cancers have progressed after at least one prior therapy. …

Matched conditions: DYSGERMINOMA

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Mar 18, 2026 14:41 UTC

DYSGERMINOMA

Get alerted when new DYSGERMINOMA trials appear

New immune therapy tested for Tough-to-Treat testicular and ovarian cancers